Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study.
Gamze Karataş, Akın Çakır, Tahsin Uzundede, Öznur Aday, Ahmet Melih Özoğuz, Mehmet Egemen Karataş, Aslı Kırmacı Kabakcı
{"title":"Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study.","authors":"Gamze Karataş, Akın Çakır, Tahsin Uzundede, Öznur Aday, Ahmet Melih Özoğuz, Mehmet Egemen Karataş, Aslı Kırmacı Kabakcı","doi":"10.18240/ijo.2025.05.13","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To investigate the efficacy and safety of repeated dexamethasone implants with real-life data in eyes with naive retinal vein occlusion (RVO) with macular edema (ME) at a minimum of 60mo follow-up.</p><p><strong>Methods: </strong>In this retrospective cohort study, the data about best corrected visual acuity (BCVA), central macular thickness (CMT), serous macular detachment (SMD), hard exudate, hyperreflective foci (HRF), cystoid degeneration, pearl necklace sign, epiretinal membrane (ERM), disorganization of retinal inner layers (DRIL), ellipsoid zone and external limiting membrane (EZ-ELM) integrity, intraocular pressure (IOP) and lens condition were recorded.</p><p><strong>Results: </strong>Thirty-eight eyes of 38 patients were included in the study. Thirteen patients presented with central RVO (CRVO) and 25 with branch RVO (BRVO). The mean follow-up time was 69.9±15.8mo, and the mean number of injections was 7.9±4.0. The mean BCVA gain was 25.0±36 letters, and this difference was statistically significant (<i>P</i>=0.021). The BCVA gain was 19.4±20.4 letters in the CRVO group, and 26.5±38.6 letters in the BRVO group (<i>P</i>=0.763). Besides, 21 (55.2%) of the patients achieved ≥15 letters improvement. At the end of the follow-up period, SMD was not observed in any of the patients (<i>P</i>=0.016). Hard exudate, HRF number were decreased; while DRIL, ERM and EZ-ELM defects were increased but not significantly.</p><p><strong>Conclusion: </strong>Intravitreal dexamethasone monotherapy is an effective and safe treatment option for the treatment-naive RVO-ME patients in the long-term follow-up.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 5","pages":"876-882"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043306/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.05.13","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To investigate the efficacy and safety of repeated dexamethasone implants with real-life data in eyes with naive retinal vein occlusion (RVO) with macular edema (ME) at a minimum of 60mo follow-up.
Methods: In this retrospective cohort study, the data about best corrected visual acuity (BCVA), central macular thickness (CMT), serous macular detachment (SMD), hard exudate, hyperreflective foci (HRF), cystoid degeneration, pearl necklace sign, epiretinal membrane (ERM), disorganization of retinal inner layers (DRIL), ellipsoid zone and external limiting membrane (EZ-ELM) integrity, intraocular pressure (IOP) and lens condition were recorded.
Results: Thirty-eight eyes of 38 patients were included in the study. Thirteen patients presented with central RVO (CRVO) and 25 with branch RVO (BRVO). The mean follow-up time was 69.9±15.8mo, and the mean number of injections was 7.9±4.0. The mean BCVA gain was 25.0±36 letters, and this difference was statistically significant (P=0.021). The BCVA gain was 19.4±20.4 letters in the CRVO group, and 26.5±38.6 letters in the BRVO group (P=0.763). Besides, 21 (55.2%) of the patients achieved ≥15 letters improvement. At the end of the follow-up period, SMD was not observed in any of the patients (P=0.016). Hard exudate, HRF number were decreased; while DRIL, ERM and EZ-ELM defects were increased but not significantly.
Conclusion: Intravitreal dexamethasone monotherapy is an effective and safe treatment option for the treatment-naive RVO-ME patients in the long-term follow-up.
期刊介绍：
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
